- Home
- SGMT vs PLX Comparison
SGMT vs PLX Comparison
Compare SGMT & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | PLX |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 182.9M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SGMT | PLX |
|---|---|---|
| Price | $10.59 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $26.13 | $12.00 |
| AVG Volume (30 Days) | ★ 1.4M | 794.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $2,000,000.00 | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.50 | $1.52 |
| 52 Week High | $11.15 | $3.19 |
Technical Indicators
Market Signals| Indicator | SGMT | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 61.30 |
| Support Level | $6.55 | $2.18 |
| Resistance Level | $11.15 | $2.71 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 70.67 | 75.70 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.